“A newly published clinical trial has revealed very serious safety concerns surrounding self-amplifying mRNA (replicon) injections—the same technology now being rapidly advanced by the FDA, BARDA, the Gates Foundation, and Arcturus Therapeutics for H5N1 bird flu…Moreover, 85.4% of participants experienced systemic adverse events such as muscle pain, joint pain, vomiting, and fever. Laboratory abnormalities intensified after the second dose, suggesting cumulative toxicity or immune priming. Concerningly, these adverse events occurred in healthy adults.”